(Q28483875)

English

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis

scientific article

In more languages

Statements

scholarly article

0 references

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis (English)

0 references

infectious disease

0 references

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

object named as

Shyam Sundar

0 references

object named as

Poonam Salotra

10

0 references

author name string

Vasundhra Bhandari

1

0 references

Arpita Kulshrestha

2

0 references

Deepak Kumar Deep

3

0 references

Olivia Stark

4

0 references

Vijay Kumar Prajapati

5

0 references

V Ramesh

6

0 references

Gabriele Schonian

8

0 references

Jean Claude Dujardin

9

0 references

language of work or name

0 references

publication date

2012

0 references

PLoS Neglected Tropical Diseases

0 references

6

0 references

5

0 references

e1657

0 references

copyright license

Creative Commons Attribution 2.5 Generic

0 references

on focus list of Wikimedia project

0 references

Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

19 March 2017

Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

19 March 2017

Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

Can visceral leishmaniasis be eliminated from Asia?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

Injectable paromomycin for Visceral leishmaniasis in India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

Visceral leishmaniasis - current therapeutic modalities.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

Miltefosine to treat leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

Advances in the treatment of leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

Oral miltefosine for Indian visceral leishmaniasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

29 September 2017

Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0001657

21 January 2018

Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0001657

21 January 2018

Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0001657

21 January 2018

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0001657

21 January 2018

Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0001657

21 January 2018

Cutaneous leishmaniasis caused by Leishmania tropica in Bikaner, India: parasite identification and characterization using molecular and immunologic tools.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

27 November 2018

A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

27 November 2018

Availability of miltefosine for the treatment of kala-azar in India.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3358331

27 November 2018

Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0001657

21 January 2018

Treatment of visceral leishmaniasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22629478

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22629478

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22629478

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PNTD.0001657

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

release_v5b2bflvpbcbbiwmmvqlbds7vq

1 reference

https://api.fatcat.wiki/v0/release/v5b2bflvpbcbbiwmmvqlbds7vq

24 November 2022

based on heuristic

mapped directly with Wikidata item

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28483875&oldid=1835561142"